ID

17648

Descripción

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Post-Treatment Assessments

Link

https://clinicaltrials.gov/ct2/show/NCT00373425

Palabras clave

Versiones (3)
  1. 7/27/16 7/27/16 -
  2. 8/1/16 8/1/16 -
  3. 9/27/16 9/27/16 -
Subido en

September 27, 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Inglés

Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios  
Vital Assessment
Descripción

Vital Assessment

Alias
UMLS CUI-1
C0031809
Date
Descripción

Assessment Date

Tipo de datos

date

Alias
UMLS CUI [1]
C2985720
Weight
Descripción

Weight

Tipo de datos

float

Unidades de medida
  • kg
Alias
UMLS CUI [1]
C0005910
kg
ECOG performance status
Descripción

ECOG

Tipo de datos

integer

Alias
UMLS CUI [1]
C1520224
Physical Examination
Descripción

Physical Examination

Alias
UMLS CUI-1
C0031809
Date Physical Examination performed:
Descripción

Examination Date

Tipo de datos

date

Alias
UMLS CUI [1]
C2826643
Pregnancy Test
Descripción

Pregnancy Test

Alias
UMLS CUI-1
C0032976
Was pregnancy test performed?
Descripción

If applicable: Was pregnancy test performed?

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032976
Date of Collection
Descripción

Date of Collection

Tipo de datos

date

Alias
UMLS CUI [1,1]
C1516698
UMLS CUI [1,2]
C0032976
UMLS CUI [1,3]
C0011008
Accession Number
Descripción

Accession Number

Tipo de datos

text

Alias
UMLS CUI [1]
C2826726
Pregnancy Test: Not Applicable
Descripción

Pregnancy Test

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032976
Biochemistry/Proteomics
Descripción

Biochemistry/Proteomics

Date of Collection
Descripción

Date of collection

Tipo de datos

date

Alias
UMLS CUI [1,1]
C0005834
UMLS CUI [1,2]
C0011008
Accession Number
Descripción

Accession Number

Tipo de datos

integer

Alias
UMLS CUI [1]
C2826726
Reason Off Treatment
Descripción

Reason Off Treatment

Reason Off Treatment
Descripción

Reason Off Treatment

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1518544
UMLS CUI [1,2]
C0566251
Specify event(s) or reason(s)
Descripción

Off Treatment Reason

Tipo de datos

text

Alias
UMLS CUI [1,1]
C1518544
UMLS CUI [1,2]
C0566251
Death
Descripción

Death

Alias
UMLS CUI-1
C0011065
Did the patient die before the Post-treatment visit?
Descripción

Did the patient die before the Post-treatment visit? (If Yes, complete section below as well as Adverse Events page and Serious Adverse Event Report Form)

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011065
Primary Cause of Death
Descripción

Primary Cause of Death

Tipo de datos

integer

Alias
UMLS CUI [1]
C0007465
If applicable, please specify primary cause of death
Descripción

Cause of death

Tipo de datos

text

Alias
UMLS CUI [1]
C0007465
Was an autopsy performed?
Descripción

Autopsy

Tipo de datos

integer

Alias
UMLS CUI [1]
C0004398
Investigator Signature
Descripción

Investigator Signature

Investigator's Signature
Descripción

I have reviewed the data recorded in this Case Report Form. To the best of my knowledge, it is a complete and accurate representation of the patient's status during the study.

Tipo de datos

text

Alias
NCI Thesaurus ValueDomain
C25704
NCI Thesaurus Property
C25678
NCI Thesaurus ObjectClass
C17089
UMLS CUI [1]
C2346576
Date
Descripción

Investigator Signature Date

Tipo de datos

date

Alias
NCI Thesaurus ObjectClass
C19464
NCI Thesaurus Property
C25250
NCI Thesaurus Property-2
C25604
NCI Thesaurus ValueDomain
C25164
NCI Thesaurus ValueDomain-2
C25367
UMLS CUI [1,1]
C2346576
UMLS CUI [1,2]
C0011008
Volver a la parte superior de la página

Similar models

Post-Treatment Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Vital Assessment
C0031809 (UMLS CUI-1)
Assessment Date
Item
Date
date
C2985720 (UMLS CUI [1])
Weight
Item
Weight
float
C0005910 (UMLS CUI [1])
ECOG
Item
ECOG performance status
integer
C1520224 (UMLS CUI [1])
Item Group
Physical Examination
C0031809 (UMLS CUI-1)
Examination Date
Item
Date Physical Examination performed:
date
C2826643 (UMLS CUI [1])
Item Group
Pregnancy Test
C0032976 (UMLS CUI-1)
Pregnancy Test
Item
Was pregnancy test performed?
boolean
C0032976 (UMLS CUI [1])
Date of Collection
Item
Date of Collection
date
C1516698 (UMLS CUI [1,1])
C0032976 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
Accession Number
Item
Accession Number
text
C2826726 (UMLS CUI [1])
Pregnancy Test
Item
Pregnancy Test: Not Applicable
boolean
C0032976 (UMLS CUI [1])
Item Group
Biochemistry/Proteomics
Date of collection
Item
Date of Collection
date
C0005834 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Accession Number
Item
Accession Number
integer
C2826726 (UMLS CUI [1])
Item Group
Reason Off Treatment
Item
Reason Off Treatment
integer
C1518544 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
Reason Off Treatment
Code List
Reason Off Treatment
CL Item
Completion of 2 years of study drug therapy (1)
CL Item
Relapse of NSCLC (Complete Relapse Report page and New Anticancer Treatment page, if applicable) (2)
CL Item
Adverse event, specify event(s) (3)
CL Item
Medical or ethical reasons, or noncompliance, following discussion between the lnvestigator and the OSI medical team (for reasons other than Adverse Event), specify reason(s) (4)
CL Item
Patient request (for reasons other than Adverse Event), specify reason(s) (5)
CL Item
Patient death (6)
Off Treatment Reason
Item
Specify event(s) or reason(s)
text
C1518544 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
Item Group
Death
C0011065 (UMLS CUI-1)
Death
Item
Did the patient die before the Post-treatment visit?
boolean
C0011065 (UMLS CUI [1])
Item
Primary Cause of Death
integer
C0007465 (UMLS CUI [1])
Primary Cause of Death
Code List
Primary Cause of Death
CL Item
NSCLC Relapse (1)
CL Item
Protocol-related toxicity, specify (2)
CL Item
Intercurrent illness, specify (3)
CL Item
Other, specify (4)
CL Item
Unknown (5)
Cause of death
Item
If applicable, please specify primary cause of death
text
C0007465 (UMLS CUI [1])
Item
Was an autopsy performed?
integer
C0004398 (UMLS CUI [1])
Autopsy
Code List
Was an autopsy performed?
CL Item
Yes (if Yes, append a copy of the autopsy report) (1)
CL Item
No (2)
Item Group
Investigator Signature
Investigator Signature
Item
Investigator's Signature
text
C25704 (NCI Thesaurus ValueDomain)
C25678 (NCI Thesaurus Property)
C17089 (NCI Thesaurus ObjectClass)
C2346576 (UMLS CUI [1])
Investigator Signature Date
Item
Date
date
C19464 (NCI Thesaurus ObjectClass)
C25250 (NCI Thesaurus Property)
C25604 (NCI Thesaurus Property-2)
C25164 (NCI Thesaurus ValueDomain)
C25367 (NCI Thesaurus ValueDomain-2)
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial